How similar are the treatment responses to biosimilars in patients with psoriasis? A systematic review of statistical margins in comparative clinical trials - 12/08/17
Funding sources: Supported in part by a National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin grant (K24 AR064310) to Dr Gelfand. |
|
Conflicts of interest: Dr Wu received research funding from AbbVie Inc, Amgen, Boehringer Ingelheim, Dermira, Eli Lilly and Company, Janssen Pharmaceutical, Novartis, Regeneron, and Sun Pharmaceutical Industries Ltd; Dr Wu is a consultant for AbbVie Inc, Amgen, Celgene, Dermira, Eli Lilly and Company, LEO Pharma, Regeneron, and Valeant Pharmaceuticals International Inc. In the previous and foreseeable 12 months, Dr Strober serves as a consultant and advisor for AbbVie Inc, Amgen, AstraZeneca, Celgene, Dermira, Janssen Pharmaceutical, Leo Pharma, Eli Lilly and Company, Cutanea-Maruho, Medac, Novartis, Pfizer, Sun Pharmaceutical Industries Ltd, Boehringer Ingelheim, UCB Inc, and Valeant receiving honoraria; received grants (paid to the University of Connecticut and not to Dr Strober himself) from AbbVie Inc, Amgen, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Eli Lilly and Company, Janssen Pharmaceuticals, Merck & Co, Sun Pharmaceutical Industries Ltd, Celgene; and serves as a scientific director for Corrona Psoriasis Registry receiving a consulting fee. In the previous 12 months, Dr Gelfand served as a consultant for Coherus BioSciences, Janssen Biologics (formerly Centocor), Merck & Co, Novartis Pharmaceuticals Corporation, Valeant Pharmaceuticals, Sanofi, and Pfizer Inc receiving honoraria; received research grants (to the Trustees of the University of Pennsylvania) from AbbVie Inc, Janssen Pharmaceuticals, Novartis Corp, Regeneron, Sanofi, Celgene, and Pfizer Inc; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Eli Lilly and Company and Abbvie Inc. Dr Gelfand is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma. No other conflicts of interest were declared. |
|
Reprints not available from the authors. |
Vol 77 - N° 3
P. 569-572 - septembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?